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ABSTRACT Lactococcus lactis subsp. lactis bv. diacetylactis BGBU1-4 produces a
novel bacteriocin, lactolisterin BU, with strong antimicrobial activity against many
species of Gram-positive bacteria, including important food spoilage and foodborne
pathogens, such as Listeria monocytogenes, Staphylococcus aureus, Bacillus spp., and
streptococci. Lactolisterin BU was extracted from the cell surface of BGBU1-4 by
2-propanol and puriﬁed to homogeneity by C18 solid-phase extraction and reversed-
phase high-performance liquid chromatography. The molecular mass of the puriﬁed
lactolisterin BU was 5,160.94 Da, and an internal fragment, AVSWAWQH, as deter-
mined by N-terminal sequencing, showed low-level similarity to existing antimicro-
bial peptides. Curing and transformation experiments revealed the presence of a
corresponding bacteriocin operon on the smallest plasmid, pBU6 (6.2 kb), of
strain BGBU1-4. Analysis of the bacteriocin operon revealed a leaderless bacteriocin
of 43 amino acids that exhibited similarity to bacteriocin BHT-B (63%) from Strepto-
coccus ratti, a bacteriocin with analogy to aureocin A.
IMPORTANCE Lactolisterin BU, a broad-spectrum leaderless bacteriocin produced by
L. lactis subsp. lactis bv. diacetylactis BGBU1-4, expresses strong antimicrobial activity
against food spoilage and foodborne pathogens, such as Listeria monocytogenes, Staphy-
lococcus aureus, Bacillus spp., and streptococci. Lactolisterin BU showed the highest
similarity to aureocin-like bacteriocins produced by different bacteria. The operon for
synthesis is located on the smallest plasmid, pBU6 (6.2 kb), of strain BGBU1-4, indi-
cating possible horizontal transfer among producers.
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Bacteria have the ability to produce an extraordinary array of different antagonisticcompounds. These include bacteriocins, described as ribosomally synthesized
hydrophobic peptides (1, 2) usually active against bacteria closely related to the
producer. In addition, some bacteriocins have broader inhibitory spectra and show
activity against medically important pathogens and food spoilage bacteria (3). On the
basis of their structures, mechanisms of action, and biochemical and genetic charac-
teristics, bacteriocins from lactic acid bacteria (LAB) are generally classiﬁed into two
different groups: class I bacteriocins (lantibiotics) contain unusual amino acids, such as
lanthionine and dehydrated amino acids, as a result of posttranslational modiﬁcations,
and class II bacteriocins consist of unmodiﬁed peptides or peptides with minor
modiﬁcations. Furthermore, class II bacteriocins are subdivided into four subclasses:
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pediocin-like bacteriocins (class IIa), two-peptide bacteriocins (class IIb), cyclic bacte-
riocins (class IIc), and linear non-pediocin-like bacteriocins (class IId) (4). The bacterio-
cins produced by LAB have been intensively explored from a fundamental perspective
for their potential applications as food preservatives and, more recently, in veterinary
and human medicine as possible alternatives to antibiotics.
The positive properties of bacteriocins that make them suitable for application in
the food industry are their lack of activity against and toxicity for eukaryotic cells and
their sensitivity to digestive proteases. The result of the latter is that they have little
inﬂuence on the gut microbiota. The application of bacteriocins in the food industry
(nisin and pediocin PA-1 are commercially available for use as food preservatives)
provides many beneﬁts; for example, they may be used as replacements for chemical
preservatives, and their use allows the intensity of heat treatment to be reduced,
resulting in food that is more naturally preserved and that has better sensorial and
nutritional properties. Furthermore, bacteriocins are relatively thermostable, and some
of them can retain antimicrobial activity following pasteurization or sterilization. Some
bacteriocins also have a broad spectrum of antimicrobial activity, so they can be used
in foods as an effective method to extend the shelf life and to control foodborne
pathogens, such as Staphylococcus aureus and Listeria monocytogenes (5, 6). L. mono-
cytogenes is of particular concern since it is the causative agent of listeriosis, a relatively
rare disease with high fatality rates in Europe (12%) and in the United States (25%), and
can traverse the intestinal, placental, and blood-brain barriers in humans. Because of
that, in most European countries and in the United States, there are zero-tolerance
standards for the presence of L. monocytogenes in ready-to-eat (RTE) food (7–10).
Traditional fermented foods, such as cheeses produced from raw milk, are a rich
ecological niche from which bacteriocin-producing LAB can be isolated (11). The
indigenous LAB isolated from white brined cheeses from Serbia are good candidates for
screening for antimicrobial substances, as they are well adapted to the microbial
environments in cheese and could therefore be the source of novel properties (12).
Aureocins are a new group of leaderless class II bacteriocins with a broad spectrum
of activity that were ﬁrst isolated from Staphylococcus aureus. Aureocins act bacteri-
cidally on sensitive cells, causing rapid lysis (13–15). According to their structure, they
can be classiﬁed into two main groups: multipeptide aureocins (aureocin 70-like
aureocins) and one-peptide aureocins (aureocin A53-like aureocins).
In a previous study, it was demonstrated that the crude extract obtained from the
cell-free supernatant of the natural isolate Lactococcus lactis subsp. lactis bv. diacety-
lactis BGBU1-4 inhibited growth and bioﬁlm formation and reduced the 24-h-old
bioﬁlms of coagulase-negative staphylococci and Listeria monocytogenes clinical iso-
lates (16). The objective of this work was to purify and biochemically and genetically
characterize the broad-spectrum bacteriocin lactolisterin BU, produced by L. lactis
subsp. lactis bv. diacetylactis BGBU1-4.
RESULTS
Localization of the genes coding bacteriocin production. The spectrum of
activity of L. lactis subsp. lactis bv. diacetylactis BGBU1-4 is broad, with the strain
inhibiting different strains of Lactococcus, Lactobacillus, Enterococcus species, and some
pathogenic strains (16). Standard biochemical methods conﬁrmed the proteinaceous
nature of the antimicrobial agent, as it was found to be sensitive to proteinase K and
pronase E. In addition, it was active against B464, a mannose phosphotransferase
(Man-PTS) deletion mutant derivative of IL1403 (17), suggesting that Man-PTS is not a
receptor for its antilisterial activity. To determine the bacteriocin-coding gene location,
a plasmid-curing assay was performed. It was interesting to note that three types of
plasmid-cured derivatives which differed in their spectra of activity and the sizes of
their inhibition zones in agar well diffusion assays were obtained. It was noticed that
derivative BGBU1-4/2 showed a reduced zone of inhibition against L. lactis subsp. lactis
BGMN1-596 and L. monocytogenes ATCC 19111 compared to that against the parental
strain and was sensitive to the parental strain. Derivatives BGBU1-4/29 and BGBU1-4/8
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did not show antimicrobial activity against BGMN1-596 or ATCC 19111 and were
sensitive to the BGBU1-4 parental strain and the derivative BGBU1-4/2. Plasmid proﬁle
analysis showed differences between parental strain BGBU1-4 and its derivatives:
derivative BGBU1-4/2 lost plasmids pBU12 and pBU20, and derivative BGBU1-4/8 lost
the smallest plasmid (pBU6) and pBU12, while in derivative BGBU1-4/29, three plasmids
(pBU6, pBU12, and pBU20) were absent (Fig. 1). These results indicate that strain
BGBU1-4 synthesizes at least two bacteriocins that are active against Lactococcus spp.
and L. monocytogenes strains and whose genes are carried by plasmids. It is possible
to conclude that there is a direct correlation between the presence and absence of
plasmid pBU6 and bacteriocin activity and most likely that the operon for the synthesis
of the second bacteriocin is located on plasmid pBU12.
Puriﬁcation and identiﬁcation of the bacteriocin(s). The bacteriocin(s) produced
by strain BGBU1-4 was puriﬁed by reversed-phase (RP) high-performance liquid chro-
matography (HPLC), and the molecular mass of the active peptides was determined by
matrix-assisted laser desorption ionization–time of ﬂight (MALDI-TOF) mass spectrom-
etry (MS). The RP-HPLC chromatogram showed dominant peaks (fractions 30 and 37)
(Fig. 2) that were active against L. lactis subsp. lactis BGMN1-596 and L. monocytogenes
ATCC 19111. Mass spectrometry analysis determined the molecular mass of fraction 30
to be 3,642.62 Da and that of fraction 37 to be 5,160.94 Da. As fraction 37 was the most
active, it was selected for further characterization.
N-terminal sequencing of protein fraction 37. N-terminal sequencing of the
native peptide in fractions 30 and 37 failed, most probably due to a blocked N terminus.
N-terminal sequencing was performed two times, without success. To circumvent this,
native peptides were digested with trypsin, and N-terminal sequencing of the internal
fragments was done. An internal 1,112.61-Da fragment of the protein from fraction 37
revealed the amino acid sequence AVSWAWQH, which corresponds to lactolisterin BU
residues 16 to 23 (see Fig. 4), while N-terminal sequencing of the peptides from fraction
30 failed two times and work was continued only with fraction 37 (lactolisterin BU).
Lactolisterin BU is a leaderless peptide, and consequently, the N-terminal amino acid is
formylmethionine rather than methionine, as there was no cleavage of the leader
peptide. The formyl group of formylmethionine blocks the alpha carbon of the amino
acid, making it inaccessible to phenylisothiocyanate (PITC), the reagent used in
N-terminal sequencing (18). MALDI-TOF MS was also used to conﬁrm the presence
of formylmethionine. Addition of a formyl group resulted in a 28-Da increase in
FIG 1 Plasmid proﬁle analysis of parental strain L. lactis subsp. lactis bv. diacetylactis BGBU1-4 and its
cured derivatives on a 1% agarose gel. Lane M, the upper part of the GeneRuler 1-kb DNA ladder (from
top to bottom, 10, 8, 6, 5, 4, 3.5, 3, 2.5, 2, 1.5, 1, and 0.75 kb; Thermo Fisher Scientiﬁc). chrom, the position
of chromosomal DNA. Only plasmids of the selected cured derivatives are shown and were taken from
different positions of the gel.
Aureocin-Like Bacteriocin in Lactococci Applied and Environmental Microbiology
November 2017 Volume 83 Issue 21 e01519-17 aem.asm.org 3
 o
n
 N
ovem
ber 18, 2018 by guest
http://aem
.asm
.org/
D
ow
nloaded from
 
mass, which was in good agreement with the 29-Da mass difference observed when
the mass of the native peptide (5,160.94 Da) was compared with the theoretical
mass (5,131.67 Da).
Heterologous expression of the bacteriocin in Lactococcus lactis subsp. cremo-
risMG7284. Plasmid curing indicated that the genes for the synthesis and immunity of
bacteriocins in strain L. lactis subsp. lactis bv. diacetylactis BGBU1-4 are located on
plasmids. The smallest plasmid from strain BGBU1-4, named pBU6 (6.2 kb), was isolated
and used for transformation of the bacteriocin nonproducer Lactococcus lactis subsp.
cremoris strain MG7284. GM17 (M17 medium supplemented with D-glucose) agar plates
containing lactolisterin BU at a concentration of 1.34 M were used to select for a
bacteriocin-resistant transformant. The transformants obtained were designated
MG7284/pBU6 and were used for further puriﬁcation of lactolisterin BU. Plasmid proﬁle
analysis of the MG7284/pBU6 transformants revealed that they all possessed the
smallest 6.2-kb plasmid and were found to be active against indicator strains BGMN1-
596, ATCC 19111, and B464, conﬁrming that Man-PTS is not a receptor for its antilisterial
activity (see Fig. S1 in the supplemental material).
Analysis of plasmid pBU6. Plasmid pBU6 was sequenced in its entirety. Analysis of
the plasmid pBU6 sequence revealed that it is a small rolling-circle replicating (RCR)
plasmid which contains nine open reading frames (ORFs): repB, lliBU, abcT, hyp1, hyp2,
hyp3, mobC, relM, and rnaseY (Fig. 3; Table 1).
In silico analysis revealed that the amino acid sequence of the RepB protein shows
a high degree of similarity to the amino acid sequences of the RepB proteins of
FIG 2 Reverse-phase high-performance liquid chromatography (RP-HPLC) chromatogram (A) and matrix-assisted laser desorption ionization–time of ﬂight
(MALDI-TOF) mass spectrometry data (B, C). Arrows, locations of the antimicrobial peptides. mAU, milli-absorbance units.
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Lactobacillus fermentum (GenBank accession no. WP_011117039.1) and Lactococcus
lactis (GenBank accession no. WP_032951507.1). The N-terminal sequencing results of
the peptide digest of fraction 37 identiﬁed lliBU to be the structural gene, encoding
a 43-amino acid (aa) peptide which is responsible for the production of the
bacteriocin lactolisterin BU. Lactolisterin BU is a leaderless bacteriocin rich in the
amino acids glycine and tryptophan (each of which comprises 11.6% of the bacte-
riocin) with a pI of 10.16. Interestingly, the amino acid sequence of this protein
shows the highest degree of similarity with that of bacteriocin BHT-B from Strep-
tococcus ratti (63%; GenBank accession no. AAZ76605.1 [19]) and other aureocin
A-like bacteriocins (Fig. 4).
TABLE 1 Results of comparison of sequences of proteins carried by plasmid pBU6 with sequences in Entrez protein database by BLAST
analysis
ORF (no. of
amino acids) Positionsa
Proteins with the highest identity
(GenBank accession no.)
Predicted domain(s) or
superfamily in encoded ORF Organism
Amino acid
sequence
identity (%)
RepB (278) 80–916 RepB (WP_011117039.1) Rep_3 (pfam01051) Lactobacillus fermentum 90
80–916 RepB (WP_032951507.1) Rep_3 (pfam01051) Lactococcus lactis 85
LliBU (43) 1034–1165 Aureocin-like bacteriocin (AAZ76605.1) Bacteriocin_Iii (pfam11758) Streptococcus ratti 63
AbcT (212) 1230–1868 Sugar ABC transporter ATP-binding protein
(WP_003089811.1)
ABC_DR_subfamily_A (CD03230) Streptococcus ratti 62
Hyp1 (212) 1861–2449 Hypothetical protein (WP_003089809.1) Streptococcus ratti 42
Hyp2 (169) 2503–3012 Hypothetical protein (AAZ76608.1) Streptococcus ratti 43
Hyp3 (92) 3531–3809 Hypothetical protein (WP_027822861.1) Lactobacillus plantarum 51
MobC (127) 3829–4212 Mobilization protein C (WP_010729194.1) MobC (pfam05713) Enterococcus faecium 41
3829–4212 Hypothetical protein (WP_011117545.1) MobC (pfam05713) Enterococcus faecalis 55
RelM (333) 4194–5195 Relaxase/mobilization nuclease
(WP_010730379.1)
Relaxase (pfam03432) Enterococcus faecium 51
RNaseY (169) 5219–5728 RNase Y (WP_017865030.1) Phosphodiesterase (PRK12704) Lactococcus lactis 29
aPositions of the gene on plasmid pBU6.
FIG 3 Circular restriction map of plasmid pBU6. Only relevant restriction sites and their positions are
indicated; unique restriction sites are indicated in bold. The positions and orientations of the genes are
indicated by arrows.
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An ORF downstream of the lliBU gene designated abcT (212 aa) encodes a protein
similar to the sugar ABC transporter ATP binding protein from Streptococcus ratti (62%;
GenBank accession no. WP_003089811.1). One or more of the next three genes, hyp1 (212
aa), hyp2 (169 aa), and hyp3 (92 aa), may encode a protein(s) that plays a role in producer
immunity. The three genes mobC (127 aa), relM (333 aa), and rnaseY (169 aa) encode
proteins similar to mobilization protein C (GenBank accession no. WP_010729194.1), relax-
ase/mobilization nuclease (GenBank accession no. WP_010730379.1), and RNase Y
(GenBank accession no. WP_017865030.1), respectively.
Biochemical characterization of lactolisterin BU. The antimicrobial activity of
puriﬁed lactolisterin BU was unchanged after heat treatment at 60°C, 80°C, and 100°C
for 15 and 30 min compared with that after no heat treatment, showing MIC values of
0.67 M against L. lactis subsp. lactis BGMN1-596 and 1.34 M against L. monocytogenes
ATCC 19111.
The growth kinetics and antimicrobial activity of transformant MG7284/pBU6 are
shown in Fig. 5. Detectable levels of bacteriocin activity were recorded after 2 h of
growth at 30°C. The maximum bacteriocin activity of the MG7284/pBU6 transformant
was achieved at the end of exponential phase, while its activity against indicator strain
Listeria monocytogenes ATCC 19111 was lower after 24 h of growth (Fig. 5).
Puriﬁed lactolisterin BU was active against various Gram-positive bacteria, with the
MICs being in the micromolar range. Lactolisterin BU showed relatively strong activity
against Listeria monocytogenes ATCC 19111, as the MIC value of the bacteriocin was
FIG 4 Alignment of the lactolisterin BU (GenBank accession no. SDR48784) amino acid sequence with the amino acid
sequences of homologous bacteriocins: lacticin Q from Lactococcus lactis QU5 (GenBank accession no. BAF57910.1), lacticin
Z from Lactococcus lactis QU14 (GenBank accession no. BAF75975.1), bacteriocin BHT-B from Streptococcus ratti (GenBank
accession no. DQ145753.1), aureocin A53 from Staphylococcus aureus (GenBank accession no. AAN71834), and an aureocin
A53-like bacteriocin from Corynebacterium jeikeium (GenBank accession no. WP_010976360). Highlighted residues indicate
conservation in at least ﬁve of the peptide sequences, while an asterisk indicates completely conserved residues. An x
corresponds to unconserved residues, periods indicate amino acids belonging to similar groups, and colons indicate amino
acids belonging to the same group.
FIG 5 Lactolisterin BU levels in culture relative to the cell density of Lactococcus lactis subsp. cremoris
MG7284/pBU6 tested on L. monocytogenes ATCC 19111. Filled squares, bacterial growth determined by
measurement of the number of CFU per milliliter; circles, the corresponding bacteriocin activity deter-
mined by the area of the zone of inhibition. Error bars represent the standard deviations from three
independent experiments.
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1.34 M. In addition, lactolisterin BU showed very strong antimicrobial activity against
Staphylococcus aureus ATCC 25923, Streptococcus pyogenes A2941, and Streptococcus
pneumoniae P156 (Table 2). It is interesting that puriﬁed lactolisterin BU exhibited
antimicrobial activity against lactolisterin BU producers (parental strain BGBU1-4, a
cured derivative BGBU1-4/2, and the MG7284/pBU6 transformant), with the MIC values
being 1.34 M (Table 2).
Mode of action of lactolisterin BU. The results of analysis of L. monocytogenes
ATCC 19111 growth in culture (starting with different numbers of cells) in the presence
of different concentrations of lactolisterin BU strongly indicated that the effect of
lactolisterin BU on growth is not growth phase dependent. The strongest lysis of
bacteria was obtained when the cells were in the early logarithmic phase. With the
increase in the number of cells, the effect of lactolisterin BU on the cessation of growth
of sensitive bacteria gradually decreased (when it was used at a concentration of 1.34
M, the MIC), but at higher concentrations (4.02 and 13.4 M), it exhibited strong
inhibition of the growth of bacteria at all stages of growth (Fig. S2), indicating that it
can successfully be used against pathogens and food contaminants that are in the
stationary phase.
An attempt to isolate a lactolisterin BU-resistant mutant. In our previous
experiences in obtaining mutants resistant to bacteriocins, we used two approach-
es: selection of spontaneous mutants and mutagenesis with N-methyl-N=-nitro-N-
nitrosoguanidine (20). We have successfully isolated mutants by the use of both
approaches, but using mutagenesis, we isolated greater numbers of mutants that
showed greater diversity. First, we tried to isolate spontaneous mutants by spreading
500 l of 10-fold-concentrated overnight cultures of sensitive strains on GM17 petri
dishes containing lactolisterin BU at concentrations of 1.34 M and 2.68 M (1 and 2
times the MIC values, respectively). No mutant resistant to lactolisterin BU was ob-
tained, indicating that the mechanism of action is possibly different from that of the
bacteriocins studied previously or that a mutation leading to resistance is lethal (that
is, the target protein is essential). In order to conﬁrm the impossibility of obtaining
mutants resistant to lactolisterin BU, banks of mutants of three sensitive strains (L. lactis
subsp. lactis BGMN1-596, L. lactis subsp. cremoris MG7284, and Enterococcus faecalis
BGZLS10-27) were constructed using N-methyl-N=-nitro-N-nitrosoguanidine (which in-
creases the chance of getting more mutations in each of the genes) and used to isolate
resistant mutants by spreading of aliquots on selective GM17 petri dishes containing
lactolisterin BU. We did not manage to select a mutant resistant to lactolisterin BU from
the mutant banks after three attempts for each strain, conﬁrming that the treatment
that we applied did not yield a mutant resistant to lactolisterin BU or it is very difﬁcult
to isolate such a mutant.
TABLE 2 Antimicrobial spectra of puriﬁed lactolisterin BU
Indicator strain MIC (M)
Lactococcus lactis subsp. lactis BGMN1-596 0.67
Lactococcus lactis subsp. lactis BGBU1-4 1.34
Lactococcus lactis subsp. lactis BGBU1-4/2 1.34
Lactococcus lactis subsp. cremoris MG7284/pBU6 1.34
Lactobacillus casei BGHN14 0.67
Listeria monocytogenes ATCC 19111 1.34
Staphylococcus aureus ATCC 25923 0.67
Enterococcus faecalis ATCC 29212 1.34
Enterococcus faecalis BGZLS10-27 1.34
Bacillus subtilis subsp. subtilis ATCC 23857 5.375
Bacillus cereus ATCC 11778 5.375
Streptococcus pyogenes 0.67
Streptococcus pneumoniae 0.67
Escherichia coli H7:O157 ATCC 35150 NAa
Pseudomonas aeruginosa ATCC 27853 NA
Salmonella Typhimurium ATCC 14028 NA
Salmonella Enteritidis ATCC 13076 NA
aNA, no activity.
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DISCUSSION
Lactic acid bacteria are found in different ecological niches, and as a result of their
efforts to adapt and survive, they produce various secondary metabolites, among which
are bacteriocins. Although bacteriocins have been studied for almost 7 decades,
researchers still ﬁnd them interesting due to their potential applications. In the last
decade, this ﬁeld has broadened because of their possible use instead of and/or in
synergy with antibiotics to overcome the immense problem of increases in the prev-
alence of antibiotic-resistant bacteria (4). Natural isolates from traditionally prepared
food products are a tremendous source of highly diverse, unique metabolites. These
isolates come from harsh environments and contain genes that are usually lost in
industrial strains. Lactococci commonly produce more than one bacteriocin, and the
Lactococcus lactis subsp. lactis bv. diacetylactis BGBU1-4 strain produces at least two
bacteriocins (21–23). The crude extract from the cell-free supernatant of strain BGBU1-4
inhibited growth and reduced the 24-h-old bioﬁlms formed by clinical isolates of
Listeria monocytogenes and coagulase-negative Staphylococcus spp., while the preven-
tion of bioﬁlm formation was demonstrated for L. monocytogenes clinical isolates (16).
The genes for the production of the bacteriocin lactolisterin BU were found to be
located on plasmid pBU6, which is not unusual (22–25), but the results of assays with
plasmid-cured derivatives of strain BGBU1-4 suggested that its broad-spectrum anti-
microbial activity is a consequence of the production of at least two bacteriocins.
Characterization of the antilisterial bacteriocin puriﬁed by HPLC revealed that the ORF
lliBU on pBU6 encodes the lactolisterin BU structural gene. In addition, sequence
analysis of lactolisterin BU, a 43-amino-acid peptide, showed that its highest similarity
was with BHT-B, a class II bacteriocin from Streptococcus ratti. Although lactolisterin BU
showed some characteristics of class IIa bacteriocins (antilisterial activity and the
absence of unusual amino acids), it does not possess the highly conserved motif
T-G-N-G-V/L generally found in pediocin-like bacteriocins with antilisterial activity and
so cannot be classiﬁed as a class IIa bacteriocin (26–28). Therefore, it is classiﬁed as a
class IId leaderless bacteriocin and can be compared to LsbB, lacticin Q, lacticin Z, and
aureocins A70 and A53, bacteriocins known to be synthesized and exported without a
leader sequence (14, 15, 23, 29, 30). A comparative analysis of the amino acid sequences
has shown that lactolisterin BU shares a conserved region, AKYGXKAV, with the majority
of known aureocin A53-like bacteriocins (Fig. 4). It can be assumed, considering the
variation in their lengths and primary structures, that the region AKYGXKAV is respon-
sible for the activity of aureocin A53-like bacteriocins. It is interesting that lactolisterin
BU shows a higher degree of identity with the BHT-B bacteriocin from Streptococcus
ratti (63%) than with lacticin Q and lacticin Z (33.9%), isolated from lactococci. The
antilisterial activity of lactolisterin BU is not mediated by interaction with Man-PTS like
that of other class II bacteriocins, as it showed antimicrobial activity against mutant
B464 (17).
Biochemical characterization showed that lactolisterin BU, like other bacteriocins, is
sensitive to proteolytic enzymes, is relatively thermostable, and is produced at maxi-
mum levels in early stationary phase (31–33). Lactolisterin BU has potential as a food
preservative due to its strong antimicrobial activity (it is active at micromolar concen-
trations) against many species of Gram-positive bacteria, including important food
spoilage and foodborne pathogens, such as Listeria monocytogenes, Staphylococcus
aureus, Bacillus spp., and Streptococcus spp. Additionally, since the production of many
food products involves exposure to high temperatures, the relative thermostability of
lactolisterin BU is another desirable feature for its application in the food industry. The
most desirable characteristic of lactolisterin BU for its use in controlling contaminants
of food or pathogens is its inability to induce resistance, which is most likely the result
of a speciﬁc mechanism of action or because it targets an essential molecule. Genes for
bacteriocin production are often located on plasmids, enabling horizontal gene transfer
between genera, and it is expected that rearrangements during transfer result in novel
peptides. It is assumed that a similar scenario happened with lactolisterin BU. The
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presence of a highly conserved region between lactococcal bacteriocin lactolisterin BU,
bacteriocin BHT-B from Streptococcus ratti, aureocin A53 from Staphylococcus aureus,
and an aureocin A53-like bacteriocin from Corynebacterium jeikeium indicates a com-
mon origin of the bacteriocin operon. It is interesting that the homologous bacteriocin
operon is present in such a wide variety of genera, which indicates that bacteriocin
production confers an advantage to the carrier. The greater similarity between lactolis-
terin BU and aureocins from other bacteria than between lactolisterin BU and lacto-
coccal bacteriocins (lacticin Q and Z) indicates that these lactococcal bacteriocins
followed a different evolutionary pathway.
This work provides insight into a new and unusual class II lactococcal bacteriocin,
lactolisterin BU. Its genetic and biochemical characteristics, spectrum of activity, pro-
tease sensitivity, thermostability, and inability to induce or the very rare occurrence of
the induction of resistance recommend lactolisterin BU as a good candidate to be a
safe, cheap, and natural food preservative. Further experiments examining the ability of
lactolisterin BU to prevent L. monocytogenes development in products obtained from
raw milk are ongoing.
MATERIALS AND METHODS
Bacterial strains and culture conditions. The bacterial strains used in this study are listed in Table
3. The bacteriocin producer L. lactis subsp. lactis bv. diacetylactis BGBU1-4 was isolated from a 3-day-old
traditional semihard cheese made from mixed cow (20%) and sheep (80%) milk (34). The cheese was
produced without the use of starter cultures in a household in the village of Buzina, located on the
mountain Beljanica in eastern Serbia. Lactococcal strains were grown in M17 medium (Merck GmbH,
Darmstadt, Germany) supplemented with D-glucose (0.5%, wt/vol) (GM17) at 30°C. Lactobacillus strains
were grown in MRS medium (Merck GmbH, Darmstadt, Germany). Nonlactococcal indicator strains were
grown aerobically in Luria-Bertani (LB) broth at 37°C. Streptococcus strains were grown in brain heart
infusion (BHI) medium (Oxoid, Basingstoke, Hampshire, England) at 37°C in atmosphere of 5% CO2. Solid
medium and soft agar were made by adding 1.5% or 0.7% (wt/vol) agar (Torlak, Belgrade, Serbia) to the
liquid medium, respectively.
Spectrum and kinetics of bacteriocin activity. The agar well diffusion assay was used to determine
the spectrum of antibacterial activity of strain BGBU1-4 (33). Each indicator strain was inoculated into
appropriate soft agar, and wells (diameter, 5 mm) were made in the plate. The wells were ﬁlled with 50
l of sample, and plates were incubated under appropriate conditions for the respective indicator strain
TABLE 3 Strains used in this studya
Strain Relevant characteristic(s) Source or reference
Lactococcus lactis
BGBU1-4 Bacteriocin (lactolisterin BU) producer 34
BGBU1-4/2 Derivative of BGBU1-4; Bac Bacs This work
BGBU1-4/8 Derivative of BGBU1-4; Bac Bacs This work
BGBU1-4/29 Derivative of BGBU1-4; Bac Bacs This work
BGMN1-596 Bac Bacs 20
MG7284 Bac Bacs 44
MG7284/pBU6 MG7284 transformed with plasmid pBU6
(producer of lactolisterin BU)
This work
B464 Man-PTS deletion mutant of strain IL1403 17
Lactobacillus casei BGHN14 Bac Bacs 45
Listeria monocytogenes ATCC 19111
Staphylococcus aureus ATCC 25923
Enterococcus faecalis ATCC 29212
Enterococcus faecalis BGZLS10-27 46
Bacillus cereus ATCC 11778
Bacillus subtilis subsp. subtilis ATCC 23857
Streptococcus pyogenes A2941 Pasteur Laboratory,
Belgrade, Serbia
Streptococcus pneumoniae P156 Pasteur Laboratory,
Belgrade, Serbia
Escherichia coli H7:O157 ATCC 35150
Pseudomonas aeruginosa ATCC 27853
Salmonella enterica serovar Typhimurium ATCC 14028
Salmonella enterica serovar Enteritidis ATCC 13076
aBac, bacteriocin producer; Bac, non-bacteriocin producer; Bacs, sensitivity to lactolisterin BU; ATCC, American Type Culture Collection, Manassas, VA, USA.
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(Table 2). After 24 h of incubation, the plates were examined for the presence of inhibition zones. A clear
zone of inhibition around the wells was taken as evidence of bacteriocin production.
To monitor the kinetics of bacteriocin production and activity, 100 ml of fresh preheated GM17 broth
was inoculated with an overnight culture (1%, vol/vol) and incubated at 30°C. Samples were taken at 0,
2, 4, 6, 8, 10, 12, and 24 h. Bacteriocin activity was determined by the area of the zone of inhibition. L.
monocytogenes ATCC 19111 and L. lactis subsp. lactis BGMN1-596 were used as indicator strains.
Genetic characterization. (i) Plasmid-curing experiments. Plasmid-curing assays were done by
growing cells of the BGBU1-4 bacterial strain in the presence of novobiocin at sublethal temperatures as
described previously (35). Preheated GM17 broth (42°C) containing novobiocin (5 g/ml) was inoculated
with 103 cells per ml. After 2 h of incubation, the cells were collected by centrifugation and resuspended
in the same volume of fresh preheated novobiocin containing GM17 broth to avoid the killing effect of
bacteriocin on the cured cells. This step was repeated four times, and endpoint aliquots (0.1 ml) were
plated onto GM17 agar plates, which were then incubated at 30°C for 48 h.
(ii) Molecular methods. Derivatives obtained following the plasmid-curing experiments and trans-
formants were conﬁrmed using pulsed-ﬁeld gel electrophoresis (PFGE) as described previously by Kojic
et al. (23). For isolation of total DNA from lactococci, a modiﬁed version of the method described by
Hopwood et al. (36) was used. Plasmid DNA from lactococci was isolated by the modiﬁed method
previously described by O’Sullivan and Klaenhammer (37). Plasmids were introduced into lactococci by
electroporation using an electroporator (Eppendorf, Hamburg, Germany) (38). Plasmid DNA was se-
quenced by the Macrogen Sequencing Service (Macrogen Europe, Amsterdam, The Netherlands). Nu-
cleotide sequences were analyzed using the BLAST algorithm. The functions of the proteins encoded by
genes carried by the pBU6 plasmid were attributed on the basis of the homology of their sequences with
those of known proteins in the Entrez Protein BLAST database, which were compared by use of the
BLAST algorithm.
Puriﬁcation of the bacteriocin. Lactolisterin BU was puriﬁed from the cells according to the method
of Rea et al. (39) with the following modiﬁcations. Brieﬂy, the cell pellet from a 2-liter culture grown in
tryptone-yeast extract broth was resuspended in 250 ml of 70% (vol/vol) 2-propanol, 0.1% (vol/vol)
triﬂuoroacetic acid (TFA) per liter of broth and stirred at room temperature for 3 to 4 h. A sample was
centrifuged at 8,280  g for 20 min, and the cell supernatant was retained for puriﬁcation. The
2-propanol was evaporated using a rotary evaporator (Buchi Labortechnik AG, Flawil, Switzerland), and
the sample was applied to a 5-g (20-ml) Strata C18-E SPE column (Phenomenex, Cheshire, UK) preequili-
brated with methanol and water. The column was washed with 40 ml of 30% (vol/vol) ethanol, and the
bacteriocin was eluted with 40 ml of 70% (vol/vol) 2-propanol, 0.1% (vol/vol) TFA. An aliquot of the 70%
2-propanol, 0.1% TFA eluent from the cell pellet passed on the C18-E SPE column was concentrated using
rotary evaporation before separation of the peptides using RP-HPLC. Aliquots of approximately 4 ml were
applied to a Phenomenex (Phenomenex, Macclesﬁeld, Cheshire, UK) Proteo Jupiter (RP)-HPLC column
(250 by 10.0 mm; particle size, 4 m; 90 Å) that had previously been equilibrated with 25% acetonitrile,
0.1% TFA. Peptides were eluted in a gradient of 30% acetonitrile containing 0.1% TFA to 70% acetonitrile
containing 0.1% TFA over 40 min with buffer A (Milli-Q water containing 0.1% TFA) and buffer B (90%
acetonitrile containing 0.1% TFA), and the ﬂow rate was 2.5 ml/min. Fractions were collected at 1-min
intervals and assayed on Lactococcus lactis BGMN1-596 and Listeria monocytogenes ATCC 19111 indicator
plates.
MALDI-TOF mass spectrometry was performed on fractions exhibiting positive inhibitory activity,
using an Axima TOF2 MALDI-TOF mass spectrometer (Shimadzu Biotech, Manchester, UK), as described
by Mills et al. (40).
N-terminal sequencing of protein from fractions 30 and 37. Protein fractions 30 and 37, which
showed antimicrobial activity, were sent to the Department of Molecular and Biomedical Sciences, Jozef
Stefan Institute (Ljubljana, Slovenia), for N-terminal sequencing by Edman degradation. N-terminal
sequencing of the native peptides failed due to the presence of an N-terminal formylmethionine, so the
peptides were digested with trypsin and the trypsin fragments were sequenced on the second attempt.
Determination of MICs. The MIC of the lactolisterin BU was determined using the broth microdi-
lution method proposed by Steinberg et al. (41). The microdilution testing assay used a mixture of the
indicator strains (Tables 2 and 3) and increasing concentrations of the bacteriocin lactolisterin BU.
Microdilution testing with in-house-prepared panels was performed following the methods of the
Clinical and Laboratory Standards Institute (42). Indicator strains were diluted to a 0.5 McFarland
standard, from which 20 l was distributed to the wells of a clear 96-well ﬂat-bottom microtiter plate.
The concentration of pure lactolisterin BU was determined by the spectroscopic method using a
theoretical extinction coefﬁcient calculated from the peptide sequence, as described by Blanusa et al.
(43). Lactolisterin BU (47 M) was 2-fold serially diluted to give a dilution series with concentrations
ranging from 43 M to 0.67 M. The microtiter plates were incubated under appropriate conditions for
24 h, and the optical density at 595 nm (OD595) was recorded at 30-min intervals (Inﬁnite M200pro; Tecan,
Switzerland). The values obtained were used to illustrate the antimicrobial activity of the bacteriocin
lactolisterin BU. Control wells contained appropriate medium (blanks) and an untreated culture. All
experiments were done in triplicate.
Effect of heat treatment on lactolisterin BU activity. Puriﬁed lactolisterin BU dissolved in water
(concentration, 47 M) was incubated at 60°C, 80°C, and 100°C for 15 min and 30 min. After the
treatments, antimicrobial activity was determined using the broth microdilution method proposed by
Steinberg et al. (41) as described above. The indicator strains were L. monocytogenes ATCC 19111 and L.
lactis subsp. lactis BGMN1-596; untreated puriﬁed bacteriocin was used as a control. All experiments were
done in triplicate.
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Mode of action of lactolisterin BU. To analyze the effect of lactolisterin BU on the growth of the
sensitive strain, puriﬁed lactolisterin BU (three different concentrations, 1.34 M [the MIC], 4.02 M [a
concentration 3 times higher than the MIC], and 13.4 M [a concentration 10 times higher than the MIC],
were used) was added to the cultures inoculated with different numbers of L. monocytogenes ATCC
19111 bacteria (3  107, 3.3  108, and 2  109 cells/ml) in microtiter plates. Before the addition of
bacteriocin, diluted bacterial cultures were incubated for 1 h at the optimal growth temperature to
refresh the cells. The bacterial growth was monitored by measurement of the OD595, which was recorded
at 30-min intervals (Inﬁnite M200pro; Tecan, Switzerland) and by determination of the number of viable
bacterial cells (number of CFU) at every hour of growth. Control wells contained appropriate medium
(blanks) and untreated cultures. All experiments were done in triplicate.
Mutagenesis of sensitive strains with N-methyl-N=-nitro-N-nitrosoguanidine. Cells of sensitive
strains (L. lactis subsp. lactis BGMN1-596, L. lactis subsp. cremoris MG7284, and Enterococcus faecalis
BGZLS10-27) from mid-logarithmic-growth phase (OD600, 0.6 to 1) were harvested by centrifugation at
10,000  g for 10 min at 4°C and washed two times in the same volume of 100 mM sodium phosphate
buffer (pH 7). Tenfold-concentrated cells in phosphate buffer were exposed to different concentrations
of N-methyl-N=-nitro-N-nitrosoguanidine (0, 25, 50, 100, and 200 g/ml in phosphate buffer) for 1 h at
30°C in the dark. After treatment, the cells were washed two times with a 10-fold volume of phosphate
buffer and, ﬁnally, resuspended in the same volume of GM17. Cultures were grown for 1 h at 30°C in the
dark in order to recover cells, and cell survival was determined by plating 10-fold dilutions on GM17
plates and incubation at 30°C for 2 days. Stabilized mutated cells were stored at 80°C in glycerol (ﬁnal
concentration, 15%) until use.
Accession number(s). The sequence of plasmid pBU6 has been submitted to the European Nucle-
otide Archive and may be found under accession no. LT629305.
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